Accelerate the Discovery, Translation & Clinical Development of Safe, Effective & Deliverable Therapies to Patients in Need
This December, 60+ thought-leaders including neuro-oncologists, neurosurgeons and oncology professionals from biopharma will be converging at the first industry led Glioblastoma Drug Development Summit under a common goal of accelerating the practical discovery, translation and clinical development of safe, effective and deliverable therapies to treat glioblastoma.
This meeting provides a truly unique platform for discussions aimed specifically at helping you not only successfully translate drug candidates into human clinical trials, but optimize the clinical development itself to avoid more clinical failures.
Gain exclusive insights into tackling specific and applied drug development challenges limiting effective therapies. This includes tumor heterogeneity, redundant pathway signalling, the immunosuppressive tumor environment and penetration through the blood-brain barrier.
With an increasing number of failed phase II trials and a very poor standard of care, there has never been a more important time to attend the Glioblastoma Drug Development Summit and join those striving to advance safe and effective therapeutic breakthroughs to patients in need.
“GBM (Glioblastoma) remains an impossibly difficult cancer not only to treat, but for which to develop effective novel therapies.
To bring together the best in the academic, patient-centric and industry spaces in order to engage in a productive dialogue, we can strive towards one new idea, one novel option, bringing even one patient a meaningful difference in her or his life.”
Jeffrey Skolnik, Vice President, Clinical Development, Inovio Pharmaceuticals
“The 1st Glioblastoma Drug Development Summit provides a unique opportunity to share our most recent findings with renowned neuro-oncology researchers and clinicians around the world, providing a platform for critical feedback and discussions that may ultimately improve on the translation of more effective therapeutics for this universally lethal disease.”
David Nathanson, Assistant Professor, UCLA